Search...
/
The Fly Cast
Press play to listen
Competitive Advantages
Superior Safety Profile: Cytisinicline has consistently demonstrated a favorable safety and tolerability profile in clinical trials, which is a significant competitive advantage over past and current smoking cessation aids.
Demonstrated Efficacy: Clinical studies have shown cytisinicline's effectiveness in helping individuals achieve smoking cessation, providing a proven therapeutic option for nicotine dependence.
Large Underserved Market: The global smoking cessation market is substantial and currently lacks a dominant, well-tolerated prescription therapy, creating a significant commercial opportunity for Achieve Life Sciences.
Risks
Clinical Trial Failure Risk: Cytisine may not achieve the desired efficacy or safety endpoints in ongoing or future clinical trials, jeopardizing regulatory approval.
Regulatory Approval Uncertainty Risk: Even with positive clinical data, Cytisine may not receive necessary regulatory approvals from health authorities such as the FDA or EMA, preventing its commercialization.
Capital Requirements and Dilution Risk: ACHV will likely require significant additional financing to fund its operations and the commercialization of Cytisine, which may not be available on acceptable terms and could lead to substantial shareholder dilution.
Over a week ago
Jun 29, 8:57 AM
Jun 26, 8:11 AM
Jun 22, 9:26 AM
May 12, 4:16 PM
May 12, 7:32 AM
Apr 21, 5:18 AM
Apr 20, 4:20 PM
Apr 16, 10:59 AM
Apr 16, 9:03 AM
Mar 24, 7:09 AM
Mar 4, 8:13 AM
Jan 23, 4:06 PM
Jan 12, 8:54 AM
Dec 30, 11:05 AM
Nov 25, 4:45 AM
Nov 6, 7:03 AM
Nov 3, 8:40 AM
Oct 20, 8:41 AM
Oct 17, 7:40 AM
